Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03306615 · ClinicalTrials.gov registry record · Phase 2
Peripheral Modulation of Muscle Stiffness and Spasticity
A Phase 2 study of Muscle Spasticity, sponsored by Johns Hopkins University.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT03306615: Active Phase 2 study of Muscle Spasticity, sponsored by Johns Hopkins University.
NCT03306615 is a Phase 2 study of Muscle Spasticity that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 56 participants, below the 75-participant average among 8 other Muscle Spasticity trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03306615, a Phase 2 study of Muscle Spasticity, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, double-blind, randomized, placebo-controlled, sequential Phase II trial of human recombinant hyaluronidase injections in individuals with post-stroke upper limb muscle stiffness. The investigators will recruit 56 subjects, who will be randomized to receive either the intervention or normal saline injections (first injection), and then the intervention the participants did not receive first (second injection). All individuals will receive the treatment by the end of the study.
Primary Outcome
passive range of motion in most affected joint across the upper limb
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hyaluronidase
Study Locations (1)
Maryland
- Johns Hopkins School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03306615 still lists
NCT03306615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 75-participant average among 8 other Muscle Spasticity trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Muscle Spasticity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03306615 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03306615 about?
NCT03306615 is a clinical study titled "Peripheral Modulation of Muscle Stiffness and Spasticity". This is a single-center, double-blind, randomized, placebo-controlled, sequential Phase II trial of human recombinant hyaluronidase injections in individuals with post-stroke upper limb muscle stiffness. The investigators will recruit 56 subjects, who will be randomized to receive either the interve...
What is the current status of trial NCT03306615?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-10-11. Estimated completion is 2026-06-30.
What conditions does trial NCT03306615 study?
This clinical trial studies the following conditions: Muscle Spasticity.
What interventions are being tested in trial NCT03306615?
The interventions under investigation include: Placebo (DRUG), Hyaluronidase (DRUG).
Who is sponsoring clinical trial NCT03306615?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03306615 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Spasticity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03306615's enrollment target sits among peer trials
56 5th of 8 higher than 4 of 8 other Muscle Spasticity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle Spasticity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Botulinum Toxin (BOTOX) for Cerebral Palsy
COMPLETED · Phase 2
-
Exoskeleton and Spinal Cord Stimulation for SCI
RECRUITING · NA
-
Dry Needling for Spasticity in Stroke
ACTIVE NOT RECRUITING · NA
-
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
COMPLETED
-
Using Telemedicine to Improve Spasticity Diagnosis Rates
COMPLETED
-
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI